The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Connect MM: The multiple myeloma (MM) disease registry—Incidence of second primary malignancies (SPM).
Robert M. Rifkin
Consultant or Advisory Role - Celgene; Millennium; Onyx
Honoraria - Millennium
Rafat Abonour
Honoraria - Celgene
Expert Testimony - Novartis
Rafael Fonseca
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Genzyme; Medtronic (U); Otsuka
Research Funding - Cylene; Proteolix
Cristina Gasparetto
Consultant or Advisory Role - Celgene
Honoraria - Celgene; Millennium
Research Funding - Celgene; Millennium
Jayesh Mehta
No relevant relationships to disclose
Mohit Narang
No relevant relationships to disclose
Chris L Pashos
Research Funding - Celgene
Sachdev P Thomas
Consultant or Advisory Role - Celgene
Jatin J. Shah
Consultant or Advisory Role - Celgene
Research Funding - Celgene
Howard R. Terebelo
Consultant or Advisory Role - Celgene
Kathleen Toomey
Consultant or Advisory Role - Celgene
Neil Minton
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Shankar Srinivasan
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Thomas Street
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Kristen Sullivan
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Brian G. Durie
Honoraria - Celgene; Millennium; Onyx (I)